New hope for Hard-to-Treat cancers: targeted pill attacks genetic weakness
NCT ID NCT06390839
First seen Oct 31, 2025 · Last updated Jun 09, 2026 · Updated 28 times
Summary
This study tests a drug called palbociclib in people with advanced cancers that have specific changes in the CDK4 or CDK6 genes. The drug works by blocking signals that tell cancer cells to grow. The goal is to see if it can shrink tumors or stop them from growing for a period of time. About 43 adults with various advanced or refractory cancers are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
Conditions
Explore the condition pages connected to this study.